Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

Strasbourg, France – Montreal, Canada – Boston, United States June 5, 2024 – Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptor (GPCR) driven immuno-resistance, today announces the publication of three international PCT patent applications.

Expanding geographic protection of Domain’s best-in-class CCR8 asset with three new patents
These patents will significantly strengthen the Company’s intellectual property protection for its series of tumor–infiltrating regulatory T cells (Tregs) depleting antibody-dependent cell-mediated cytotoxicity/ phagocytosis (ADCC/ADCP) anti-CCR8 antibodies, including DT-7012, a novel drug candidate with best-in-class potential compared to other clinical-stage CCR8 antibodies. Currently in the pre-IND stage of development, DT-7012 is set to commence Phase I clinical trials in early 2025.

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “These three new patents are pivotal to our strategy, enhancing our robust patent estate and expanding our reach across diverse market opportunities. They underscore the broad international application of our Treg depleting ADCC/ADCP anti-CCR8 antibodies, particularly for our lead anti-CCR8 candidate DT-7012. They also reinforce Domain’s position as an industry leader in GPCR-mediated immunotherapies. Notably, this timely publication of PCT patent applications aligns with our accelerated and broadened research and development efforts in immuno-oncology.”

Improving clinical outcomes in cancer patients via strategic depletion of T regulatory cells in the tumor microenvironment
CCR8 is a GPCR target specifically expressed by tumor infiltrating Tregs, major immunosuppressive cells responsible for the failure of several therapeutics in the clinic, which makes this target highly strategic for the development of efficient novel immunotherapies.


For more information, please contact:
ICR Consilium

Amber Fennell, Namrata Taak, Andrew Stern
Tel: +44 (0)20 3709 5813

Yucatan (for French media)
Annie-Florence Loyer
Tel: +33 (0)

About Domain Therapeutics
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer differently, using a precise biomarker strategy to address the specific needs of patients based on unique signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by multiple pharma partnerships, associated to a target identification and drug discovery platform enable the Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.

Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary cross-validation drug discovery and development platform.

Domain is part of the SPRINT university hospital research project (RHU), a French consortium, led by Dr Adèle DE MASSON, directed by Paris Cité University and funded by the French government as part of the France 2030 implemented by ANR, to advance precision medicine for patients with cutaneous T-cell lymphoma.

Since 2022, the Company raised €51m ($55m) in series A to progress preclinical and clinical development of its high-value drug candidates to address GPCR-mediated immunosuppression. Domain is supported by leading international venture capital firms from Europe (3B Future Health Fund, Seventure, Schroders, Omnes, Turenne, Theodorus), Asia (Panacea and Viva) and North America (CTI Life Science, adMare).

For more information, please visit: